Uniqure NV News - UQ1

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s...

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an...

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease...

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction...

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress ~ Presented promising clinical update from U.S. and European...

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease ~ Patients treated...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease Patient enrollment...

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced FDA clearance of Investigational...

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting LEXINGTON, Mass. and AMSTERDAM, Oct...

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs ~...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy...

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of...

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress ~ Data from largest gene therapy study in hemophilia B showed...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1)

Empower your portfolio: Real-time discussions and actionable trading ideas.

UQ1 News

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

UQ1 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1) News

Uniqure NV (UQ1)

Empower your portfolio: Real-time discussions and actionable trading ideas.

UQ1 News

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

UQ1 Discussion

Your Recent History